Busan, South Korea

Tae Jun Wang

This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Pohang University of Science and Technology Foundation. Active years: 2017.

USPTO Granted Patents = 1 

% Patents Active = 100.0

Average Co-Inventor Count = 7.0

ph-index = 1


Company Filing History:


Years Active: 2017

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Tae Jun Wang: Innovator in Cell Labeling Technologies

Introduction

Tae Jun Wang is a prominent inventor based in Busan, South Korea. He has made significant contributions to the field of biotechnology, particularly in the methods of labeling cells with fluoroquinolone antibiotics. His innovative work has implications for various biological applications.

Latest Patents

Tae Jun Wang holds a patent for "Methods of labeling cells with fluoroquinolone antibiotics." This patent provides methods for labeling cells in biological tissues, bacteria, and fungi using fluoroquinolone antibiotics such as moxifloxacin and gatifloxacin. This advancement enhances the ability to study and manipulate cells in medical and research settings.

Career Highlights

Wang is affiliated with the Pohang University of Science and Technology Foundation, where he continues to engage in groundbreaking research. His work is characterized by a commitment to improving methodologies in cell labeling, which is crucial for advancements in medical research and treatment.

Collaborations

Tae Jun Wang has collaborated with notable colleagues, including Ki Hean Kim and Myoung Joon Kim. These partnerships have fostered a collaborative environment that enhances the quality and impact of their research.

Conclusion

Tae Jun Wang's contributions to the field of biotechnology through his innovative patent and collaborative efforts highlight his role as a key figure in advancing cell labeling technologies. His work continues to influence research and applications in the medical field.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…